Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Opioids Market to 2018 - Introduction
2.1 Introduction
2.1.1 High Levels of Product Diversification in a Highly Competitive Market Environment
2.1.2 Inconsistent Clinician Prescribing Preferences
2.1.3 Ongoing Market Shift Towards Abuse-Resistant Product Formulations
2.1.4 Increasingly Vocal Physician Associations Raise Concerns About Extent of Opioid Abuse
2.1.5 Full Commercial Potential of Transdermal Patches May Have Yet to be Fully Exploited
3 Opioids Market to 2018 - Overview of Currently Marketed Products
3.1 Major Marketed Products
3.1.1 Oxycontin
3.1.2 Exalgo
3.1.3 Onsolis
3.1.4 Duragesic
3.1.5 Opana ER
3.1.6 Vicodin CR
3.1.7 Dolophine Hydrochloride
3.1.8 Oxecta
3.1.9 Actiq
3.1.10 Embeda
3.1.11 Kadian
3.1.12 Avinza
3.2 Market Drivers and Barriers
3.2.1 Drivers
3.2.2 Barriers
4 Opioids Market to 2018 - Pipeline Analysis
4.1 Introduction
4.2 Opioid Compounds in the Developmental Pipeline
4.3 Distribution by Route of Administration
4.4 Promising Pipeline Products
4.4.1 ARX-01, AcelRX Pharmaceuticals
4.4.2 ALO-02, Pfizer
4.4.3 Zohydro ER, Zogenix
4.4.4 ELI-216, Elite Pharmaceuticals
4.4.5 BEMA Buprenorphine
4.4.6 CEP-33237, Cephalon
5 Opioids Market to 2018 - Deals Analysis
5.1 Overview:
5.1.1 M&As by Year
5.1.2 M&As by Value
5.1.3 Major M&As
5.2 Licensing Agreements
5.2.1 Licensing Agreements by Year
5.2.2 Licensing Agreements by Value
5.2.3 Major Licensing Agreements
5.3 Co-Development Agreements
5.3.1 Deals by Year
5.3.2 Major Co-Development Deals
6 Opioids Market to 2018 - Appendix
6.1 Abbreviations
6.2 Bibliography
6.3 Research Methodology
6.3.1 Coverage
6.3.2 Secondary Research
6.3.3 Primary Research
6.3.4 Pipeline Analysis
6.3.5 Expert Panel Validation
6.4 Contact Us
6.5 Disclaimer